Über das Unternehmen

Elpen’s activities include product development, production, regulatory affairs, marketing, sales, and exports. R&D is performed in 1.000m2 facilities focusing on cardiology, endocrinology, cancer, respiratory diseases and OTC. Examples of R&D activities include the Elpenhaler® DPI products already introduced in the EU markets, such as Formopen® (formoterol), Fluticapen® (fluticasone) and Rolenium® (salmeterol/fluticasone combination). We possess full production lines of Oral Solids, Oral Liquids, Dry Powder Inhalation, Injectable, Lyophilized products and a dedicated facility for the production of Oral Solid Penicillin.

GR
Nicht verifiziertes Unternehmen